Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012

  Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver
  Disease and Fibrosis at AASLD 2012

Business Wire

NORCROSS, Ga. -- October 26, 2012

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, today announced
that it will present at the American Association for the Study of Liver
Disease (AASLD) Annual Meeting on November 12, 2012, in Boston, MA.

Preclinical data have demonstrated the ability of the Company’s lead galectin
inhibitor compound, GR-MD-02, to prevent and reverse the formation of fibrosis
in animal models of non-alcoholic steatohepatitis (NASH), or fatty liver
disease. The presentation at AASLD will extend understanding about the
mechanism by which GR-MD-02 improves pathology in NASH, an important unmet
medical need.

Details of the presentation are as follows:
Session: NASH: Basic
Time: Monday, November 12, 2012, 8:30 am – 5:30 pm ET
Title: Galectin-3 targeting drugs inhibit multiple pathological pathways
leading to improvement of non-alcoholic steatohepatitis (NASH)
Authors: Peter G. Traber and Eliezer Zomer

About NASH
NASH is a common disease of the liver, affecting 9 to 15 million people in the
United States. NASH is characterized by the presence of fat in the liver along
with inflammation and damage in people who drink little or no alcohol. Over
time, patients with NASH can develop fibrosis, or scarring of the liver, that
can lead to cirrhosis, a severe liver disease where transplantation is the
only current treatment available.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.


Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
Press spacebar to pause and continue. Press esc to stop.